Technology area: Biotechnology & Pharmaceuticals
27 pending office actions • 18 clients • 26 examiners • 20 art units • 0 of 27 (0%) have an AI response strategy ready
Cermak & McGowan LLP has 27 pending office actions in Biotechnology & Pharmaceuticals and 2652 career applications. The current docket is supported by a substantial application record, giving practitioners context for assessing both ongoing prosecution and experience in the technology area.
The resolved allowance rate is 82.86%, with an average of 3.8 office actions per allowance. The allowance figure reflects favorable resolution across the recorded matters, while the action average shows that successful prosecution commonly includes multiple examination exchanges. Applicants can use this combination to consider response planning, amendment strategy, and the practical effort associated with reaching allowance.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (4%) |
| §103 only | 4 (15%) |
| §102 only | 1 (4%) |
| §112 only | 1 (4%) |
| Double-patenting + other | 4 (15%) |
| Multi-statute (no §101) | 15 (56%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, BRYAN | 2 | 28.2% | +36.6% |
| BORROMEO, JUANITO C | 1 | 76.3% | +13.3% |
| ELOSHWAY, NIKI MARINA | 1 | 63.5% | +24.6% |
| ALAM, AYAAN A | 1 | 38.8% | +36.4% |
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
| BEHARRY, ZANNA MARIA | 1 | 25.0% | +56.3% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| MCWILLIAMS, KELSEY LYNN | 1 | 89.2% | +5.8% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| MOEHLMAN, ANDREW TERRY | 1 | 67.0% | +59.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18734393 | Method for Producing Protein | MCWILLIAMS, KELSEY LYNN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799466 | A PROCESS FOR THE PRODUCTION OF A BAKED PRODUCT WITHOUT ADDITION OF SUGAR | TRAN, LIEN THUY | 73d overdue |
| 17193141 | Consumable Product Comprising Malted Wheat | KIM, BRYAN | 31d overdue |
| 17999081 | Use of SAA, rSAA or inhibitors of SAA in the treatment of dysregulated inflammation | JUEDES, AMY E | 17d overdue |
| 18250643 | Anti-Microbial Skin-Care Composition Comprising Beta-Glucan and Natural Oil | WEBB, WALTER E | 15d overdue |
| 18065167 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | HIRT, ERIN E | 12d |
| 18558029 | A METHOD AND A SYSTEM FOR MANUFACTURING A PROTEIN-RICH BIOMASS COMPRISNG EDIBLE FILAMENTOUS FUNGUS | KIM, BRYAN | 42d |
| 19112410 | Mounting element for panels and method for fastening panels to a support structure | ELOSHWAY, NIKI MARINA | — |
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17193141 | Consumable Product Comprising Malted Wheat | KIM, BRYAN | 31d overdue |
| 18558029 | A METHOD AND A SYSTEM FOR MANUFACTURING A PROTEIN-RICH BIOMASS COMPRISNG EDIBLE FILAMENTOUS FUNGUS | KIM, BRYAN | 42d |
| 19239096 | Circuit Integration | BORROMEO, JUANITO C | — |
| 19112410 | Mounting element for panels and method for fastening panels to a support structure | ELOSHWAY, NIKI MARINA | — |
| 18937758 | Multi-Functional Cleaning and/or Debridement Composition | ALAM, AYAAN A | — |
| 18904277 | Method for Preparing a Three-Dimensional Scaffold for Medical Use | MOAZZAMI, NAGHMEH NINA | — |
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | BEHARRY, ZANNA MARIA | — |
| 18631361 | BACTERIUM MODIFIED TO EXPRESS HETEROLOGOUS Tat PROTEIN | BARRON, SEAN C | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Ajinomoto | 7 |
| Lantmännen | 3 |
| Meridian Therapeutics, Inc. | 2 |
| Televic Rail | 1 |
| Dissing A/S | 1 |
| CORTICALIS AS | 1 |
| Askel Heathcare Ltd. | 1 |
| The Jikei University | 1 |
| Millow Holding AB | 1 |
| Lallemand | 1 |
| Evolva S.A. | 1 |
| Mcbi Inc. | 1 |
| Morinaga Milk | 1 |
| ALPS BIOTECH CO., LTD. | 1 |
| Lika Antisepsis | 1 |
| Hunilife | 1 |
| Ajinomoto Co., Inc. | 1 |
| Lantmännen Unibake Holding A/S | 1 |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1652 | 2 |
| 1653 | 2 |
| 1655 | 2 |
| 1792 | 2 |
| 1616 | 2 |
| 1793 | 2 |
| 2184 | 1 |
| 3736 | 1 |
| 1632 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19239096 | Circuit Integration | Televic Rail | BORROMEO, JUANITO C | 2184 | §103 | Non-Final OA | — | Pending | Jun 16, 2025 |
| 19112410 | Mounting element for panels and method for fastening panels to a support structure | Dissing A/S | ELOSHWAY, NIKI MARINA | 3736 | §102§103 | Non-Final OA | — | Pending | Mar 17, 2025 |
| 18937758 | Multi-Functional Cleaning and/or Debridement Composition | Corticalis AS | ALAM, AYAAN A | 1611 | §103§112DP | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18904277 | Method for Preparing a Three-Dimensional Scaffold for Medical Use | Askel Heathcare Ltd. | MOAZZAMI, NAGHMEH NINA | 1652 | §103DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18836116 | Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte | The Jikei University | BEHARRY, ZANNA MARIA | 1632 | §102§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18750252 | Composition for Culturing Animal Cells | Ajinomoto Co., Inc. | CANDELARIA, JULIANA IRENE | 1634 | §102§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18734393 | Method for Producing Protein | Ajinomoto Co., Inc. | MCWILLIAMS, KELSEY LYNN | 1663 | §112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18631361 | BACTERIUM MODIFIED TO EXPRESS HETEROLOGOUS Tat PROTEIN | Ajinomoto Co., Inc. | BARRON, SEAN C | 1653 | §102§103 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18401960 | Method for Secretory Production of Unnatural-Amino-Acid-Containing Protein | Ajinomoto Co., Inc. | MOEHLMAN, ANDREW TERRY | 1655 | §103§112 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18574224 | COMPOSITIONS AND METHODS OF TREATING PLASMA CELL DISORDERS INCLUDING MULTIPLE MYELOMA WITH A VACCINE COMPOSITION AND MYELOMA-SPECIFIC CAR-T CELLS | Meridian Therapeutics, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18574219 | A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using Same | Meridian Therapeutics, Inc. | WEIDNER, ADAM M | 1675 | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18558029 | A METHOD AND A SYSTEM FOR MANUFACTURING A PROTEIN-RICH BIOMASS COMPRISNG EDIBLE FILAMENTOUS FUNGUS | Millow Holding AB | KIM, BRYAN | 1792 | §103§112 | Final Rejection | 42d | Pending | Oct 30, 2023 |
| 18354140 | COSMETIC COMPOSITION | Ajinomoto Co., Inc. | SAEED, ALI S | 1616 | §103§112 | Final Rejection | — | Pending | Jul 18, 2023 |
| 18350982 | METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE | Danstar Ferment AG | KOROTCHKINA, LIOUBOV G | 1653 | §103§112DP | Non-Final OA | 49d overdue | Pending | Jul 12, 2023 |
| 18351225 | METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE | Evolva SA | MEAH, MOHAMMAD Y | 1652 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18270073 | JUDGMENT SUPPORTING INFORMATION GENERATING METHOD, JUDGMENT SUPPORTING INFORMATION GENERATING SYSTEM, AND INFORMATION PROCESSING DEVICE | Mcbi Inc. | FUELLING, MICHAEL | 3992 | §101§103§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18256080 | Prebiotic Composition for Butyric Acid Bacteria | Morinaga Milk Industry Co., Ltd. | GALSTER, SAMUEL LEONARD | 1693 | §102 | Final Rejection | 70d overdue | Pending | Jun 06, 2023 |
| 18250643 | Anti-Microbial Skin-Care Composition Comprising Beta-Glucan and Natural Oil | Lantmännen Oats AB | WEBB, WALTER E | 1612 | §103§112 | Final Rejection | 15d overdue | Pending | Apr 26, 2023 |
| 18246797 | Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases | Alps Biotech Co., Ltd. | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18065167 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | Ajinomoto Co., Inc. | HIRT, ERIN E | 1616 | §102§103§112 | Non-Final OA | 12d | Pending | Dec 13, 2022 |
| 17999081 | Use of SAA, rSAA or inhibitors of SAA in the treatment of dysregulated inflammation | Lika Antisepsis Gbr | JUEDES, AMY E | 1644 | §103§112 | Non-Final OA | 17d overdue | Pending | Nov 17, 2022 |
| 17998559 | DRUG CONJUGATES CONTAINING ALPHA-ENOLASE ANTIBODIES AND USES THEREOF | Hunilife Biotechnology, Inc. | HAQ, SHAFIQUL | 1678 | §103 | Final Rejection | 72d | Pending | Nov 11, 2022 |
| 18048519 | Method For Producing Soy Sauce-Like Seasoning | Ajinomoto Co., Inc. | MCCLAIN, TYNESHA L. | 1793 | §102§103§112 | Non-Final OA | — | Pending | Oct 21, 2022 |
| 17910175 | A Consumable Product Comprising Malted Cereals for Promoting Recovery at Physical Activity | LANTMÄNNEN FUNCTIONAL FOODS AB | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | 35d overdue | Pending | Sep 08, 2022 |
| 17799466 | A PROCESS FOR THE PRODUCTION OF A BAKED PRODUCT WITHOUT ADDITION OF SUGAR | Lantmännen Unibake Holding A/S | TRAN, LIEN THUY | 1793 | §103§112 | Non-Final OA | 73d overdue | Pending | Aug 12, 2022 |
| 17713804 | Surfactant and Composition | Ajinomoto Co., Inc. | ISNOR, ALEXANDRA NICOLE | 1611 | Other | Non-Final OA | 17d overdue | Pending | Apr 05, 2022 |
| 17193141 | Consumable Product Comprising Malted Wheat | LANTMÄNNEN FUNCTIONAL FOODS AB | KIM, BRYAN | 1792 | §103 | Final Rejection | 31d overdue | Pending | Mar 05, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial82.9% of resolved applications prosecuted by Cermak & Mcgowan LLP were allowed, across 2,652 applications in USPTO records.
3.80 office actions per allowed application on average.
27 pending office actions as of October 2026, for 18 clients, before 26 examiners in 20 art units.
